"Biological effects of soluble recombinant CD40 ligand on human breast cancer cell lines in vitro and in vivo."

“可溶性重组 CD40 配体对人乳腺癌细胞系的体外和体内生物学效应。”

• 批准号: 09671257
• 负责人: KOBAYASHI Tadashi
• 金额: $ 0.96万
• 依托单位: JIKEI UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09671257/
• 关键词: CD40; breast cancer; SCID mouse; SCIDマウス; アポプトーシス

1. Surface expression of CD4O on human breast cancer cell line. Immunofluorescence studies were performed by flow cytometric analysis. CD4O was expressed on human breast cancer cell line, MDA-231.2. Antitumor effects of soluble recombinant CD4O ligand (srCD4OL) on human breast cancer cell lines in vitro. Incubation with srCD4OL significantly inhibited the proliferation of MIDA-231 as determined by the proliferation assay with optimal inhibition of thymidine incorporation and MTT assay(p<0.05). Apoptotic studies by flow cytometry revealed an induction of apoptosis in MDA-231.3. Antitumor effects of Lym-2 treatment in SCID mice bearing human B-cell lymphomas. Effects of srCD4OL treatment on survival in tumor-bearing SCID mice were determined. All mice received 20 muL of anti-asialo GM1 (Wako Chemicals, Osaka) by intravenous injection (IV) 1 day before tumor transfer to remove host natural killer cells.MDA-231 cells (5x10^6) were then administered by IV.SCID recipients then received either 10 mug of srCD40L, anti-CD4OAb or control every other day for 20 days for total of 10 injections starting at day 3. Tumor bearing mice were then monitored for tumor development and progression. Treatment with srCD40L significantly improved the survival of tumor-bearing mice (p<0.05).We presented this data st Annual Meeting of Research for Breast Cancer, 1997 May, Tokyo.

1.人乳腺癌细胞系表面CD 4 O的表达通过流式细胞术分析进行免疫荧光研究。CD 4 O在人乳腺癌细胞系MDA-231.2上表达。可溶性重组CD 4 O配体（srCD 4 OL）对人乳腺癌细胞系的体外抗肿瘤作用用最佳抑制胸苷掺入的增殖试验和MTT试验测定，与srCD 4 OL孵育显著抑制MIDA-231的增殖（p<0.05）。通过流式细胞术进行的凋亡研究揭示了MDA-231.3中的凋亡诱导。Lym-2治疗在携带人B细胞淋巴瘤的SCID小鼠中的抗肿瘤作用。测定srCD 4 OL治疗对荷瘤SCID小鼠存活率的影响。所有小鼠在肿瘤转移前1天通过静脉注射（IV）接受20穆尔抗去唾液酸GM 1（和子Chemicals，Osaka）以去除宿主自然杀伤细胞。然后通过IV施用MDA-231细胞（5 × 106）。然后SCID受体每隔一天接受10 μ g srCD 40 L、抗CD 4 OAb或对照，持续20天，从第3天开始总共注射10次。然后监测荷瘤小鼠的肿瘤发展和进展。用srCD 40 L治疗显著提高了荷瘤小鼠的存活率（p<0.05）。我们在1997年5月东京乳腺癌研究年会上发表了这一数据。